- Development of inhibitors against lipase and α|glucosidase from ...🔍
- All About Inhibitors🔍
- Pharmacology and Clinical Development of Factor XI Inhibitors🔍
- Key Findings🔍
- Recombinant Factor VIII for the Treatment of Previously Untreated ...🔍
- Counteracting coagulation🔍
- Intensity of factor VIII treatment and the development of inhibitors in ...🔍
- Hemophilia Inhibitors 101🔍
Development of Inhibitors
Development of inhibitors against lipase and α-glucosidase from ...
The three derivatives all functioned as noncompetitive inhibitors against lipase, whereas the h-pen derivative acted as a mixed type of inhibitor against α- ...
All About Inhibitors - Canadian Hemophilia Society
25 to 50% of people with severe hemophilia A. (factor VIII deficiency) will develop inhibitors. Not all of these inhibitors will be serious. 1.5 to 5% of people ...
Pharmacology and Clinical Development of Factor XI Inhibitors
This article reviews the rationale, pharmacology, results of medium or small phase 2 studies, and future perspectives of drugs inhibiting FXI.
Key Findings: Antibody Type / Inhibitor Development Link
Inhibitors are types of antibodies that develop against clotting factor products used to treat bleeding in people who have hemophilia.
Recombinant Factor VIII for the Treatment of Previously Untreated ...
... Development of Inhibitors. Authors: Jeanne M. Lusher, Steven Arkin ... The pathogenesis of inhibitor formation and the reason why some inhibitors ...
Counteracting coagulation: Inhibitor development in hemophilia A
This thesis focuses on inhibitor development in hemophilia A and addresses risk factors and immunological mechanisms driving inhibitor ...
Intensity of factor VIII treatment and the development of inhibitors in ...
SUMMARY: Background Inhibitor development is a major complication of treatment with factor VIII concentrates in hemophilia. Findings from studies among severe ...
Hemophilia Inhibitors 101 - HemAware
Anyone with hemophilia A or B, or VWD type 3, who infuses clotting factor concentrates may develop an inhibitor. Most often inhibitors develop ...
Risk factors for inhibitor development in severe hemophilia A
Inhibitors develop from a multicausal im- mune response involving both genetic (unmodifiable) and environmental (modifiable) factors. F8 gene ...
Can T-cell and B-cell excision circles predict development ... - Nature
Our findings may add to the notion that inhibitor formation is attributed to humoral immunity due to peripheral B-cell expansion and production ...
A Guide to the Management of Patients with Inhibitors to Factor VIII ...
Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol. 2007;138:305-315. 4. Lollar, P. Pathogenic antibodies to ...
Development of proteasome inhibitors as research tools and cancer ...
The proteasome is the primary site for protein degradation in mammalian cells, and proteasome inhibitors have been invaluable tools in ...
Discovery and development of HIV-protease inhibitors - Wikipedia
Mechanism of action · There are several steps in the HIV life cycle that may be interfered with, thus stopping the replication of the virus. A very critical ...
The clinical development of inhibitors of poly(ADP-ribose) polymerase
Inhibitors of poly(ADP-ribose) polymerase (PARP) are of particular interest in treating hereditary breast cancers occurring in patients who are carriers of ...
Inhibitors > Complications > HoG Handbook > Hemophilia of Georgia
The most common time of inhibitor development is in the first few exposures to factor therapy. Many physicians will quote the first 20-50 exposures as the ...
Clinical development of metabolic inhibitors for oncology - JCI
Here we review small-molecule metabolic inhibitors currently in clinical development for oncology applications.
Cancer growth blockers | Targeted cancer drugs
Cancer growth blockers are also called cancer growth inhibitors. They are a type of targeted cancer drug. Our body makes chemicals called growth factors that ...
Bleeding Disorders and Inhibitors - Paragon Healthcare
Any person with a bleeding disorder can develop an inhibitor at any time, but it is usually in the first year or two of life. Having recently ...
Drug development of MET inhibitors: targeting oncogene addiction ...
MET tyrosine kinase has a central role in cell motility, proliferation and protection from apoptosis — properties that can transform it into a powerful ...
Recent advances in the development of covalent inhibitors
The use of covalent inhibitors in the field of drug discovery has attracted considerable attention in the 2000s. As a result, more than 50 covalent drugs ...
mTOR inhibitors
Class of drugsmTOR inhibitors are a class of drugs used to treat several human diseases, including cancer, autoimmune diseases, and neurodegeneration.
Discovery and development of HIV-protease inhibitors
Many major physiological processes depend on regulation of proteolytic enzyme activity and there can be dramatic consequences when equilibrium between an enzyme and its substrates is disturbed.
c-Met inhibitor
c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor.
Discovery and development of ACE inhibitors
The discovery of an orally inactive peptide from snake venom established the important role of angiotensin converting enzyme inhibitors in regulating blood pressure. This led to the development of captopril, the first ACE inhibitor. When the adverse effects of captopril became apparent new derivates were designed.
Development of: Design of specific inhibitors and active site probes for legumain
Statin
Class of drugsStatins are a class of medications that reduce illness and mortality in people who are at high risk of cardiovascular disease. Low-density lipoprotein carriers of cholesterol play a key role in the development of atherosclerosis and coronary heart disease via the mechanisms described by the lipid hypothesis.